Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation  by Bartelink, Imke H. et al.
From the
Cente
Hema
Cente
maceu
of He
Utrec
ter for
versit
Leide
Financial d
Correspon
Pharm
D00.2
i.barte
Received A
1083-8791
doi:10.101Association between Busulfan Exposure and Outcome
in Children Receiving Intravenous Busulfan before
Hematologic Stem Cell Transplantation
Imke H. Bartelink,1 Robert G. M. Bredius,2 Svetlana V. Belitser,3 Marit M. Suttorp,2
Marc Bierings,4 Catherijne A. J. Knibbe,5 Maarten Egeler,2 Arjan C. Lankester,2
Atoine C. G. Egberts,1 Juliette Zwaveling,6 Jaap Jan Boelens4Busulfan, combined with therapeutic drug monitoring–guided dosing, is associated with higher event-free
survival (EFS) rates due to fewer graft failures/relapses and lower toxicity. The optimal target area under
the curve (AUC) and dosing schedule of intravenous busulfan in children undergoing hematopoietic stem
cell transplantation (HSCT) remain unclear, however. We conducted a retrospective analysis of the associ-
ation between busulfan exposure and clinical outcome in 102 children age 0.2 to 21 years who received bu-
sulfan 1 or 4 times daily before undergoing HSCT (46 malignant and 56 nonmalignant indications). EFS and
overall survival after a median of 2 years of follow-up were 68% and 72%, respectively. EFS was optimal when
the exposure of busulfan (AUC) was 78 mg*h/L (95% confidence interval 5 74 to 82 mg*h/L). Acute graft-
versus-host disease (aGVHD) grade II–IVoccurred more frequently with greater busulfan exposure. The ad-
dition of melphalan was an independent risk factor; melphalan use combined with high busulfan exposure
(AUC . 74 mg*h/L) was associated with high incidences of aGVHD (58%), veno-occlusive disease (66%),
and mucositis grade III-IV (26%). Dosing frequency (1 or 4 times daily) was not related to any outcome. In
conclusion, dose targeting of busulfan to a narrow therapeutic range was found to increase EFS in children.
Adding melphalan to optimal busulfan exposure is associated with a high incidence of toxicity.
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Busulfan is widely used in preparative chemother-
apy-based regimens, being an alternative for total body
irradiation in patients undergoing hematopoietic stem
cell transplantation (HSCT) for malignant and non-
malignant diseases [1–3]. Until recently, busulfan was1Department of Clinical Pharmacy of University Medical
r Utrecht Utrecht, The Netherlands; 2Department of
tology and Immunology of Leiden University Medical
r, Leiden, The Netherlands; 3Utrecht Institute for Phar-
tical Sciences, Utrecht University, Utrecht; 4Department
matology and Immunology of University Medical Center
ht, Utrecht, The Netherlands; 5Leiden/Amsterdam Cen-
Drug Research, Division of Pharmacology, Leiden Uni-
y, Leiden; and 6Department of Clinical Pharmacy of
n University Medical Center.
isclosure: See Acknowledgments on page 238.
dence and reprint requests: Imke H. Bartelink, PharmD,
acy, UMC Utrecht, Heidelberglaan 100, PO Box
18, 3584 CXUtrecht, The Netherlands (e-mail:
link@umcutrecht.nl).
ugust 11, 2008; accepted November 13, 2008
/09/152-0001$36.00/0
6/j.bbmt.2008.11.022available only in oral form and was administered 4
times daily. The therapeutic potential of the oral
drug is current under debate, due to the highly variable
intraindividual and interindividual and unpredictable
systemic exposure related to its pharmacokinetic prop-
erties, especially in children [4–7]. To reduce the
variability of busulfan exposure, intravenous (i.v.) for-
mulations of busulfan have been developed recently.
Despite these formulations, however, considerable
interindividual variability in busulfan exposure has
persisted in adults and, to an even greater degree, in
children [8–16].
An advantage of the i.v. formulation of busulfan is
the reduced number of daily doses compared with the
oral preparation. The latter must be administered ev-
ery 6 hours, mainly because only 2-mg tablets are avail-
able. In contrast, i.v. busulfan can be given once a day,
increasing convenience for both patients and care-
givers. In addition, it might be postulated that once-
a-day dosing may reduce toxicity, because the patient
is not continually exposed to busulfan during the
day, given the drug’s short half-life (approximately 2
hours in children). This extended period between
doses might allow recovery of glutathione-S-reductase231
232 Biol Blood Marrow Transplant 15:231-241, 2009I. H. Bartelink et al.and glutathione-S-transferase (GST), the enzymes re-
sponsible for the metabolism of busulfan, which might
reduce toxicity [17–19].
The therapeutic window of busulfan is narrow;
a high exposure (expressed as the area under the curve
[AUC]) has been associated with increased risk of
toxicities, such as mucositis, acute graft-versus-host
disease (aGVHD) and veno-occlusive disease (VOD)
[2,20-22]. In contrast, low exposure to busulfan has
been associated with increased incidence of graft rejec-
tion and relapse [23,24]. Dose targeting of oral busul-
fan based on therapeutic drug monitoring (TDM) has
improved clinical outcomes in pediatric HSCT recip-
ients [3,7,25,26]. However, the optimal dose, optimal
AUC target, and dosing schedule of i.v. busulfan in
children remain undecided [16,27].
We conducted a retrospective analysis of a cohort
of pediatric patients who underwent HSCT and had
a wide range of exposure to busulfan. The aim was to
establish the optimal busulfan exposure in relation to
efficacy and toxicity.METHODS
Setting and Study Population
All pediatric patients who underwent transplanta-
tion between August 2000 and March 2007 in the
HSCT units of the Leiden University Medical Center
(LUMC) and the University Medical Center Utrecht
(UMCU) receiving i.v. busulfan–based myeloablative
conditioning combined with TDM were included in
this study. All data were collected prospectively. Pa-
tients were enrolled in the HSCT and research proto-
col after providing written informed consent and
receiving institutional ethical committee approval.Transplantation Details, Conditioning
Regimens, and Supportive Care
HLA-matching was based on high-resolution
(HR) typing for class I and class II (10 alleles) for fam-
ily and unrelated bone marrow (BM) or peripheral
blood stem cell (PBSC) donors. For cord blood (CB)
donors, intermediate resolution criteria were used
(low resolution for loci HLA-A, -B, and -DRB1 by
HR typing). A HLA-DPB1 mismatch was not taken
into account. For the analyses, the patients were di-
vided into a matched group and a mismatched group,
with 1 or more allele or antigen mismatches defined
as a mismatch. CB grafts were considered matched (6
antigens) when they were identical according to the
aforementioned intermediate resolution criteria.
All patients received conditioning according to ap-
plicable international and national protocols. Busulfan
(Busilvex; Pierre Fabre Medicament, Boulogne,
France) was given as the first-line agent, followed by
cyclophosphamide after at least 24 hours. Based onthese protocols, melphalan, fludarabine, or etoposide
also was given to some patients. In general, a combina-
tion of busulfan (Bu), cyclophosphamide (Cy), and
melphalan (Mel) was used in patients with myeloid
malignancies, myelodysplastic syndrome (MDS), and
acute lymphoblastic leukemia (ALL), as well as in
some patients with thalassemia or hemoglobinopathy.
Bu and Cy, combined with fludarabine (Flu) in some
cases, was administered for nonmalignant indications;
Bu, Cy, and etoposide (VP16) was administered in
patients with hemophagocytic lymphohistiocytosis
(HLH), as well as some younger patients (age \ 3
years) with ALL.
All patients were cared for in high-efficiency,
particle-free, air-filtered, positive-pressure isolation
rooms. Unrelated donors received serotherapy (either
antithymoglobulin [ATG]-rabbit or alemtuzumab
[both from Genzyme, ]). GVHD prophylaxis consisted
of cyclosporine (Sandimmune iv, Neoral po; Novartis
Pharma BV). Methotrexate (10 mg/m2 on days 11,
13, and 16) was added to the recipients of non–T
cell-depleted grafts, and recipients of an unrelated
CB donor graft also received prednisone (1 mg/kg) un-
til day 128 (tapered in 2 weeks in patients without
aGVHD). Patients who received CB were treated
with filgrastim (Neupogen; Amgen Europe BV,)
from day 17 until a neutrophil level . 2000/mL was
achieved.
Gut decontamination and infection prophylaxis
was given according to the institutional protocol. No
VOD prophylaxis was given. VOD was treated with
defibrotide, diuretics, and fluid restriction. Patients re-
ceived standard antiemetic drugs (ondansetron) and
prophylactic anticonvulsive therapy (clonazepam) dur-
ing busulfan therapy. The conditioning regimen re-
mained fixed throughout the study period, except for
the busulfan dosing regimen. From 2003 onward, the
frequency of CB transplantations increased, with T
cell depletion performed less often. The medical and
nursing staff’s familiarity with CB transplantation
increased during the study period.
Intravenous Busulfan Regimen and Therapeutic
Drug Monitoring
Busulfan was administered intravenously over a 4-
day period. The dose and target AUC of busulfan were
modified 3 times during the study period (as shown in
Table 2), producing 3 groups of patients with different
dosing schedules. The first group of patients received
busulfan 4 times a day for 4 consecutive days. The
starting dose was 1.0 mg/kg for patients under age 4
years and 0.8 mg/kg for those age 4 years and older,
similar to the adult dose. Dose adjustment was allowed
to a limit of 1.0 mg/kg every 6 hours if the target AUC
of 4.93 mg hr/L was not achieved [28]. The second
group received a once-daily busulfan regimen. The
starting dose was 80 mg/m2 and subsequent doses
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third group received an initial dose of 120 mg/m2
(age $ 1 year) or 80 mg/m2 (age\1 year) [30]. These
patients were targeted to an AUC of 17.5 mg*h/L.
Modifications to the regimen were introduced based
on experience and after an initial analysis and publica-
tion of data [28-30]. The current study included both
those patients reported previously and those treated
more recently with i.v. busulfan.
Busulfan concentrations were analyzed by high-
pressure liquid chromatography, based on the method
described by Cremers et al. [10] and Zwaveling et al.
[28]. Calculation of the AUC was based on at least 3
blood samples (obtained 1, 2, and 3 or 4 hours after
the end of infusion) on day 11, using a single-
compartment model with linear pharmacokinetics
established by Cremers and coworkers [10,28,30].
Empirical Bayesian pharmacokinetic parameter
estimates (clearance and volume of distribution) were
estimated using the pharmacokinetic software package
MwPharm [31]. Busulfan dose was adjusted only when
the AUC differed by . 10% from the target AUC. If
possible, an evaluation of the AUC after dose adjust-
ment was performed on a subsequent day and was
used to calculate the total busulfan exposure.
Busulfan exposure (ie, total AUC over 4 days) in all
patients was calculated by the sum of the daily (extrap-
olated) AUC measurements. If 2 AUC measurements
were performed, then the AUC after dose adjustment
was extrapolated to the other 2 days on which the
same dose was used: AUC1 1 AUC2  3. If the
AUC after dose adjustment was not measured, then
the results of day 11 were extrapolated to days 12,
13, and 14: AUC1 1 (AUC1  new dose/old dose)
 3. If no dose adjustment was performed and the sec-
ond AUC differed from the first AUC, then both
AUCs were extrapolated to the other days on which
no blood samples were measured (AUC1  2 1
AUC2  2).Endpoints
The main study endpoints were event-free survival
(EFS) and overall survival (OS) after HSCT, with a fol-
low up of at least 6 months. EFS was defined as alive
with engraftment (. 95% chimerism) and without ev-
ident relapse in those children who underwent trans-
plantation for malignant disease.
Toxicity endpoints were VOD, moderate/severe
(. grade I) aGVHD, severe (. grade II) mucositis,
and acute lung toxicity (ie, bronchiolitis obliterans or
idiopathic pneumonia syndrome). VOD was diag-
nosed according to the modified Seattle criteria [30].
Severity of VOD was graded according to the system
of Bearman [32]. Baseline VOD risk was defined ac-
cording to criteria described in a VOD defibrotide
prophylaxis study [33]. aGVHD was diagnosed andgraded according to the criteria of Glucksberg et al.
[34], and oral mucositis was evaluated and scored based
on World Health Organization criteria [35]. Because
melphalan was used as a second alkylating agent in
the conditioning regimen in many patients (42%; Ta-
ble 1), we studied the inclusion of melphalan as an ad-
ditional risk factor for toxicity and main endpoints.
Chimerism . 95% was considered full donor chime-
rism; donor chimerism. 10% and\95% was consid-
ered mixed chimerism.Statistical Analysis
The association between busulfan exposure and
the endpoints (EFS, OS, toxicity) were analyzed using
univariate and multivariate Cox proportional hazards
regression models, stratified by clinical center
(UMCU or LUMC), using SPSS version 12.1 (SPSS
Inc, Chicago, IL). Because of the different dosing reg-
imens, patients receiving a broad range of doses and
having widely varying busulfan exposures were avail-
able. To perform covariate analysis, the patients were
separated into 5 equal groups (quintiles), each group
comprising 20 patients, based on total AUC of busul-
fan. Univariate predictors of outcome that were statis-
tically significant (P value \ .05) were selected for
multivariate analysis. Results are expressed as esti-
mates of hazard ratios (HRs) and corresponding 95%
confidence intervals (95% CIs). Additional analyses
were performed to study the optimal busulfan expo-
sure. In these analyses, the total AUC of busulfan
was modeled as a continuous variable in a multivariate
Cox regression model. The optimum was estimated
for the outcome parameter EFS, using a proportional
hazards model of regression in R version 2.6.1. The
95% CI of the optimum was constructed using the
delta method with R library ‘‘alr3.’’RESULTS
Patient Characteristics
Between August 2000 and March 2007, 106 pa-
tients received conditioning containing busulfan in
the 2 Dutch pediatric HSCT units. Four patients
who received a reduced-intensity busulfan regimen
were excluded from the analysis; thus, 102 patients
(46 with malignant disease and 56 with nonmalignant
disease) patients were analyzed in this study (Table 1).
The patients in the 5 groups defined by AUC were
comparable for all variables except dosing regimen and
center of inclusion (Table 1). The 4-times-daily dose
was not evenly distributed among the quintiles, be-
cause dosing was maximized in the 4-times-daily regi-
men, generally resulting in relatively low exposure
(median, 56 mg*h/L in the patients receiving the 4-
times-daily regimen and 72 mg*h/L in those receiving
Table 1. Patient Characteristics (n 5 102)
Distribution over
5 AUC groups*
P value
Follow-up, weeks, median (range) 102.2 (0.3 to 364) .229
Age, years, median (range) 3.1 (0.2 to 21.0) .520
Busulfan dosing regimen, n
Once daily 64 <.001
4 times daily 38
Sex, n
Male 57 .763
Female 45
Diagnosis, n
Malignant† 46 .993
Nonmalignant‡ 56
Pretreatment, n§
None 58 .063
Chemotherapy, low intensity 14
Chemotherapy, high intensity 30
Conditioning, n¶
Bu/Cy/Mel 43 .851
Other Bu-based 59
Serotherapy, n
No 19 .778
Yes 83
Stem cell source, n
BM 60 .563
CBk 27
PBSCs 15
Donor, n**
Matched 57 .507
Mismatched 45
T cell depletion, n††
No 79 .182
Yes 23
VOD risk, n‡‡
No 40 .966
Yes 64
Center, n§§
LUMC 71 <.001
UMCU 31
Busulfan total AUC, mg*h/L, median (range) 69.6 (30.6 to110.6)
Bu, i.v. busulfan; Cy, cyclophosphamide; Mel, melphalan; Flu, fludarabine;
Eto, etoposide.
Hemoglobinopathies included thalassemia and sickle cell anemia. Other
nonmalignant disorders included paroxysmal biogenesis defect,
NOMID-like (Neonatal-onset multisystem inflammatory disease).
*Differences in distributions of patient characteristics over the 5 AUC
percentiles were tested with 1-way analysis of variance for continuous
normally distributed variables, the Kruskal-Wallis test for not normally
distributed continuous variables, and the Pearson c2 test for categorical
variables.
†Malignancies included (number of patients; disease status): AML (2), in-
fant ALL (9; 4 ALL/complete remission [CR]1, 4 CR2, 1 CR3), lymphoma
(1), chronic myelogenous leukemia [CML] (1), MDS (25; 7 RA, [refrac-
tory anemia] 5 RAEB, [refractory anemia with excess blasts] 6 RAEBt,
[refractory anemia with excess blasts in transformation] 1 RARS,
[refractory anemia with ringed sideroblasts] 5 MDS/AML, 1 MDS/
CML), JMML (8; 4 patients untreated, 2 patients in CR, 2 received treat-
ment without intent to achieve remission).
‡Nonmalignant disorders included BM failure syndromes (n5 4), inborn
errors of metabolism (n 5 22), and immunodeficiencies and hemoglo-
binopathies (n 5 30). BM failure included aplastic anemia, Diamond
Blackfan anemia, congenital amegakaryocytosis., Shwachman syndrome.
Inborn errors of metabolism included osteopetrosis, X-ALD (X-adre-
noleukodystrophy), MLD (metachromatic leukodystrophy), Gaucher’s
disease, and Hurler’s disease. Immunodeficiencies included severe
combine immunodeficiency, HLH, Chediak-Higashi syndrome, WAS
(Wiskott-Aldrich Syndrome), ICF syndrome, X-LPD, (X-linked lympho-
proliferative disease) Omenn syndrome, and others.
§All leukemia remission induction and maintenance protocols. HLH in-
duction (HLH1994 and 2004 protocol) was considered high-intensity
pretreatment. Low-intensity pretreatment was considered any low-
dose chemotherapy with the intent of not to cure but rather to control
the disease.
¶Other Bu-based regimens (number of patients): Bu/Cy (47), Bu/Cy/Flu
(6), Bu/Cy/Eto (5), and Bu/Flu (1). In general, a combination of Bu, Cy,
and Mel was used for myeloid malignancies, MDS, and ALL and in
some patients with thalassemia or hemoglobinopathy. Bu and Cy and,
in selected cases, Flu was given for nonmalignant indications, and Bu,
Cy, and etoposide (VP16) was given to patients with HLH as well as
some younger patients (age < 3 years) with ALL.
kMedian number of nucleated cells in CB grafts was 8.6 107/kg (range,
2.7 to 23  107/kg).
**Related donors (number of patients): matched sibling (18), matched
family (4), mismatched family (2), haploidentical (6). Unrelated donors
(number of patients): matched (34), mismatched unrelated (38). Mis-
matches (number of patients): BM, 1-antigen mismatched (9), 2-antigen
mismatched (4); CB, 1-antigen mismatched (16), 2-antigen mismatched
(7); PBSCs, 1-antigen mismatched (3). Sixteen patients (72%) with mis-
matched unrelated (BM or PBSC) donors received T cell depletion, ver-
sus 7 patients (21%) with matched unrelated (BM/PBSC) donors.
††T cell depletion was performed by various methods, including CD34+
selection or the addition of Campath in the bag, and was performed for
various reasons, including haploidentical transplants, young infants, and
large mismatched donors. In the matched donor group, 7 patients (12%)
had T cell depletion, whereas in the mismatched group, 16 patients had
T cell depletion (36%). None of the CB transplants were T cell depleted.
‡‡VOD risk5 preexistent liver disease$ second myeloablative HSCT,
previous treatment with gemtuzimab ozogamicin, leukemia beyond sec-
ond relapse, osteopetrosis, conditioning with Bu + Mel, macrophage-
activating syndromes, adrenoleukodystrophy.
§§Further analyses were stratified for the center of inclusion.
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that neither the 4-times-daily nor the once-daily regi-
men influenced the main outcome or the toxicity out-
come (data not shown). The LUMC center included
more patients in the low total AUC percentiles; there-
fore, stratified Cox regression was performed with
center of inclusion as a stratification factor.Therapeutic Drug Monitoring of Busulfan
The results based on the 3 dosing regimens are
given in Table 2. The study population exhibit a wide
range in total AUC, from 31 mg*h/L to 110 mg*h/L
(1860 to 6740 mmol*min/day). Large interindividual
variations in the pharmacokinetics of busulfan were ev-
ident, necessitating varying dose adjustments at day12
to14 of busulfan treatment. Dose adjustments differed
among the 3 dose-targeting regimens, as shown in
Table 2. The AUC was measured after dose adjustment
in 50% of the patients; 48% received a total AUC
within 10% of the total targeted AUC after 4 days of
busulfan treatment (Table 2).Main Endpoints: Overall Survival and Event-Free
Survival
Overall EFS was 68%, and OS was 72%. All pa-
tients engrafted except 3 patients who died within
the first 3 weeks after transplantation. Eleven patients
Table 2. Characteristics of Dosing Regimens
Dosing Characteristic Dose regimen 1 Dose regimen 2 Dose regimen 3
Number 38 16 48
Total target AUC in 4 days, mg*h/L 78.8 62.4 70
Starting dose, mg/day Age < 4 years: 4 mg/kg in 4 doses
Age $ 4 years: 3.2 mg/kg in 4 doses
(maximum subs. dose 4 mg/kg)
80 mg/m2 once daily Age < 1 year: 80 mg/m2 once daily
Age $ 1 year: 120 mg/m2 once daily
Follow-up, weeks, median (range) 249 (2 to 364) 120 (5 to 196) 62 (0.3 to 148)
Total AUC, mg*h/L, median (range) 56.3 (31 to 94) 57.1 (35 to 65) 77.5 (46 to 111)
AUC within 10% of total target AUC 30% 75% 52%
% decreased doses 5% 0% 51%
% increased doses 47% 84% 15%
% no dose change 47% 16% 34%
The 3 dosing regimens are shown. For each of these groups, the percentage of dose adjustments performed and the total AUC calculated within the
various groups are shown.
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whom 2 died and 9 experienced graft failure.
In univariate analysis, busulfan exposure, HLA dis-
parity, serotherapy, cell source, and age were predictors
influencing EFS and OS (P\.05). In multivariate anal-
ysis, a busulfan exposure of 72 to 80 mg*h/L (4400 to
4900 mmol*min/day) was associated with the highest
EFS and OS (P 5 .028 and .021, respectively). This is
demonstrated in the Kaplan-Meier curve of EFS in as-
sociation with increasing exposure to busulfan shown
in Figure 1A. An increased AUC of busulfan was asso-
ciated with a lower incidence of graft failure and relapse
(HR 5 0.47; P 5 .004), as shown in Figure 1B. Multi-
variate analysis found that 2 other covariates indepen-
dently influenced EFS and OS: HLA disparity (HR 5
3.79; P 5 .001) and age at time of HSCT (HR 5 1.12
for each year of age; P 5 .001).Optimum Busulfan Exposure
Figure 2 shows the results of further analysis eval-
uating busulfan exposure as a continuous variable
rather than a categorical variable in relation to EFS.
The events experienced by all patients demonstrate
that the model generally describes the data well. The
Cox regression model produced an optimum AUC of
74 to 82 mg*h/L (4500 to 5000 mmol*min/day),
very similar to the analysis using AUC as categorical
variable.
In addition, 2 other models were designed to dem-
onstrate how the covariates could influence the concen-
tration–response relationship: one for the mismatched
donors and one for matched donors (curves are shown
in Addendum 2), with an optimum of 75 to 85 mg*h/L
for mismatched donors and 65 to 77 mg*h/L for
matched donors (in children age\ 10 years). Age af-
fected all models similarly. EFS was linearly associated
with age, being lower in older children.Toxicity Endpoints
Moderate/severe aGVHD ($ grade II) occurred in
16% of the patients, VOD occurred in 22%, andmucositis grade III-IV occurred in 12%. Figure 3
shows the association between exposure to busulfan
and the incidence of adverse effects. In both univariate
and multivariate analyses, busulfan exposure was a sig-
nificant predictor for aGVHD (HR5 1.56; P5 .019),
but not for VOD (HR 5 1.11; P5 .508) or mucositis.
Lung toxicity was seen in 11 patients (3 with bronchio-
litis obliterans and 8 with idiopathic pneumonia
syndrome), all independent of the AUC of busulfan.
The addition of melphalan was an independent
risk factor for the occurrence of aGVHD (HR 5
3.04; P5 .042), VOD (HR5 2.23; P5 .069), and mu-
cositis (HR 5 9.02; P 5 .005) in multivariate analysis.
The relationship between the busulfan exposure and
toxicity was compared in patients in whom melphalan
was and was not included in the conditioning regimen.
The incidences of aGVHD and VOD were approxi-
mately 3-fold higher (HR 5 3.6: P 5 .019) in the 12
patients treated with a combination of busulfan (.
74 mg*h/L), cyclophosphamide, and melphalan (58%
aGVHD; 66% VOD) compared with the 23 patients
who received the same AUC of busulfan but without
melphalan (17% aGVHD; 17% VOD) (Figure 4).
Severe mucositis occurred in 26% of the patients who
received melphalan, but in only 3% of those who did
not receive melphalan, independent of busulfan exposure.
In the patients treated with busulfan, cyclophos-
phamide, and melphalan, busulfan exposure correlated
with aGVHD and VOD (Figure 4). The incidences of
both were higher in the patients receiving this condi-
tioning regimen with a high busulfan exposure (. 74
mg*h/L) compared with those treated with the same
conditioning regimen but with a low busulfan expo-
sure (\ 74 mg*h/L) (VOD, 66% vs 16% [HR 5 4.1;
P 5 .012]; aGVHD, 58% vs 13% [HR 5 4.5; P 5
.016]).DISCUSSION
Our findings demonstrate that the therapeutic
window for i.v. busulfan in children is rather narrow
when used in an ablative conditioning regimen before
Figure 2. Cox regression models of busulfan exposure in relation to
EFS for all patients. The event (death, relapse, or graft failure) in the
matched and mismatched patients and these patients corresponding ex-
posure to busulfan are shown separately (1, event; 0, no event). The Lo-
ess curves (displays of the mean data) for the EFS of all data are shown
for the matched and mismatched groups. The events occurring in all pa-
tients during the first 26 weeks of follow-up (the minimum follow-up
time) are shown. After this 26-week period, 5 additional events oc-
curred: 3 patients relapsed, and 2 patients died due to TRM. All events
are included in the model, in which the total follow-up time is described.
A third-order polynomial model, b1*AUC1 b2*AUC
21 b3*AUC
3, can
describe these data (black line).
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Figure 3. Toxicity endpoints in relation to total AUC of busulfan. Each
symbol represents a new patient added to the busulfan exposure–toxic-
ity relationship.
Figure 1. (A) Kaplan-Meier curves of 5 groups based on total AUC and
EFS. (B) Kaplan-Meier curves of 5 groups based on total AUC and graft
failure/relapse.
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5000 mmol*min/day) was associated with the highest
EFS in children with malignant and nonmalignant dis-
eases. Two additional covariates influencing EFS and
OS were HLA disparity and age. Increased toxicity
was associated with higher busulfan exposure, espe-
cially when melphalan was part of the conditioning
regimen.
The optimal therapeutic window in these children
was found to be 74 to 82 mg*h/L, which is in line with
the range in adults (60 to 100 mg*h/L [3600 to 6000
mmol*min/day]) [8]. The optimum value resulting
from the analysis of the continuous function was quite
similar to that resulting from the analysis using AUCas a categorical variable, demonstrating the consis-
tency of the analyses.
Below a total AUC of 74 mg*h/L, EFS was nega-
tively influenced by graft failure or relapse, whereas
above this range, no graft failures occurred, and only
1 patient relapsed. The relatively high rate of rejection
(9%) could be due to T cell depletion in this popula-
tion, however. The patients with a busulfan exposure
. 82 mg*h/L exhibited a very high incidence of toxic-
ity, leading to increased mortality [16,36].
The incidence of toxicity in this study was high
compared with similar studies [15,16]. Toxicity was re-
lated mainly to the addition of melphalan to the condi-
tioning regimen in combination with high busulfan
Toxicity endpoints in association with busulfan
exposure in the presence and absence of melphalan
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Figure 4. Toxicity endpoints in relation to busulfan exposure in the
presence and absence of melphalan. Each symbol represents a new
patient added to the busulfan exposure–toxicity relationship of patients
treated with and without melphalan.
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found a high toxicity rate [26,30,37]. The high inci-
dence of toxicity possibly could be linked to depletion
of GST by high exposure to busulfan, because the me-
tabolites of cyclophosphamide and melphalan are me-
tabolized by the same enzyme system (GST) [26]. This
mechanism potentially could increase the combined
toxicity of busulfan and cyclophosphamide and mel-
phalan metabolites, as has been demonstrated in
a model using murine hepatocytes [38]. The high inci-
dence of toxicity in the patients who received condi-
tioning with busulfan, cyclophosphamide, and
melphalan also may be associated with the indication
for transplantation. In the present study, the choice
of drugs used in the conditioning regimen depended
on indication; thus, we cannot totally exclude the
covariables of indication or disease risk on the expo-
sure–outcome relationship. The patients who did not
receive melphalan (those receiving busulfan plus cyclo-
phosphamide, fludarabine, or etoposide) demon-
strated no association between VOD and busulfan
exposure, in line with previous studies [16,36]. Lung
toxicity was not associated with busulfan exposure.
Busulfan is associated mainly with later-onset lung
toxicity, however. Given our limited follow-up period
(2 years for the whole group), we are unable to com-
ment on the risk of late-onset lung toxicity related to
busulfan exposure [33,39-42].
Optimal busulfan exposure apparently leads to
higher EFS, but the combination of busulfan and
melphalan proved to be highly toxic in the patients
treated in this study. In the past, melphalan was added
to busulfan (given orally, without TDM) and cyclo-
phosphamide in patients with MDS to reduce the
risk of graft failure and relapse [43]. Because of the
variable bioavailability of busulfan, the exposure tooral busulfan was generally much lower [6] than the
optimum level defined in this study. A subgroup of
our patients with myeloid leukemia (acute myeloid
leukemia [AML]/MDS or juvenile myelomonocytic
leukemia [JMML]), all of whom received melphalan,
demonstrated a relationship between the AUC of bu-
sulfan and the incidence of failure or relapse; 7 of 27
patients (25%) with a busulfan exposure\ 74 mg*h/
L had relapse or graft failure, compared with 0 of 8 pa-
tients with a busulfan exposure$ 74 mg*h/L (P5 .11).
These data suggest that sufficient ablation might
already be reached with optimal busulfan exposure;
thus, it is tempting to speculate that melphalan might
not be necessary in the era of targeted busulfan. Simi-
larly, in adults, conditioning with targeted busulfan
with cyclophosphamide and, more recently, the com-
bination of busulfan and fludarabine has proven very
effective in patients with AML/MDS. This combina-
tion has a safer toxicity profile compared with cyclo-
phosphamide and melphalan [44,45] and appears to
be more effective (ie, fewer relapses and lower TRM)
[44,46]. Fludarabine inhibits lymphocyte prolifera-
tion, resulting in potent immune suppression. In addi-
tion, it prevents alkylator-induced DNA repair and
thus could be synergistic with busulfan in its tumor-
killing effect. Further analyses and optimization of bu-
sulfan exposure in reduced- toxicity regimens, such as
busulfan and fludarabine, as well as validation in ran-
domized trials, could provide more definitive answers
to these questions.
In addition to busulfan exposure, 2 other covariates
influenced the outcomes in this study: HLA disparity
and age. Patients with a mismatched donor had
a much lower EFS than those with a matched donor.
This influence of HLA disparity on the outcome of
HSCT is in line with the literature [47-52], but, to
the best of our knowledge, this has never before been
related to the optimal busulfan exposure. Our findings
suggest that patients receiving transplants from
matched donors might require a lower busulfan expo-
sure, whereas in a mismatched setting, optimal abla-
tion is more important to prevent rejection and
autologous reconstitution. We considered that with
less busulfan exposure in the mismatch setting, more
residual, potentially alloreactive cells (host-versus-
graft direction) may remain in the recipient, with the
potential for clinical rejection/relapse. Because of the
high EFS, the matched model was not as accurate as
the mismatched model. The inclusion of more (young)
patients may clarify the optimal busulfan exposure in
matched donors.
Older age negatively affected OS, in line with most
previous pediatric HSCT studies. Older children
seemed more prone to TRM, such as aGVHD and
reactivation of viral infections (data not shown).
Although a prospective, randomized trial is the
best study design for determining the optimal
238 Biol Blood Marrow Transplant 15:231-241, 2009I. H. Bartelink et al.exposure to busulfan, such a study is made complicated
by important ethical issues. Changes to the busulfan
dosing regimen were introduced based on available ex-
perience; therefore, we felt that a retrospective study
of patients in whom all data were prospectively docu-
mented was the best available method. All patients
were treated in the same way with regard to
indication-associated conditioning regimens and sup-
portive care. Over time, 2 changes were made in the
protocol; T cell depletion was decreased, and the num-
ber of CB transplantations was increased. Although T
cell depletion was not found to influence the study
endpoints, CB transplantation negatively influenced
OS. But CB transplantations were divided equally
among the quintiles of busulfan exposure and thus
were not expected to influence the exposure–outcome
relationship. In addition, the wide range of diseases
included and the retrospective character of the study
represent limitations in this respect.
The busulfan dosing regimen (4 times daily or
once daily) did not influence any of the outcomes. In
earlier studies, it was hypothesized that reducing the
exposure to busulfan may be associated with less toxic-
ity; the use of once-daily dosing could allow enzyme
recovery of glutathione-S-reductase and GST between
doses [17-19]. But our findings suggest that the dosing
regimen had no influence on outcomes, which is in line
with a recent randomized study in adults [19]. Once-
daily dosing has the same outcome, is feasible, and cer-
tainly is much more convenient for the patient, the
pharmacy, and caregivers.
A large interindividual variation in AUC of busul-
fan was found in this study, similar to the findings of
other studies with intravenous busulfan [11,53].
Many patients required dose changes based on the re-
sults of TDM and the target AUC. Our data show that
OS and EFS may be improved by narrow targeting to
a therapeutic window of busulfan exposure, necessitat-
ing TDM. The importance of TDM was highlighted
in a study in adults in which a dose based on lean
body mass resulted in a 4-fold range in AUC among
patients and a significant increase in toxicity when an
exposure . 100 mg*h/L was reached [1,2,5,6,12,36].
Although TDM showed improved results, some pa-
tients were still exposed to an AUC that differed
from the targeted AUC. Thus, it seems that analysis
of the variability in pharmacokinetics (PK) and phar-
macodynamics (PD) using population PKPD model-
ing, in combination with an identification of
covariates that account for this variability, is needed.
This will lead to a predictable AUC and effectivity/
safety profile in these pediatric patients.
In conclusion, our findings indicate that the out-
come of HSCT in pediatric patients can be improved
by TDM-adjusted dose targeting to a narrow thera-
peutic range of busulfan of 74 to 82 mg*h/L ( 4500
to 5000 mmol*min/day). Once-daily dosing is feasible,is associated with similar outcomes as for 4-times-daily
dosing, and is more practical and patient- and staff-
friendly than 4-times-daily dosing. Melphalan in com-
bination with an optimally targeted busulfan dose was
associated with severe toxicity, suggesting that in this
era of high AUC targeted busulfan dosing, the role
of melphalan as a second alkylating agent should be re-
considered. Prospective studies with busulfan target-
ing this narrow AUC in less toxic regimens, such as
busulfan and fludarabine, should help further improve
the outcomes of HSCT in children.ACKNOWLEDGMENTS
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APPENDIX 1: Univariate Analysis o
EFS
Covariate n Events, n (%) P H
AUC busulfan 30 to 55 mg*h/L 21 9 (43) 1
55 to 65 mg*h/L 20 7 (35) .529 0.7
65 to 72.5 mg*h/L 20 7 (35) .545 0.7
72.5 to 80 mg*h/L 21 3 (14) .035 0.2
80 to 110 mg*h/L 20 7 (35) .400 0.6
HLA disparity Matched 57 12 (21) 1
Mismatched 45 21 (47) .004 2.9
Conditioning No melphalan 59 15 (25) 1
Melphalan 43 18 (42) .083 2.1
Busulfan regimen 4 daily doses 38 12 (32) 1
1 daily dose 64 21 (33) .736 1.1
T cell depletion No 79 23 (29) 1
Yes 23 10 (43) .148 1.8
Serotherapy No 19 2 (10) 1
Yes 83 30 (36) .035 4.6
Age .008 1.0
Sex Male 57 20 (35) 1
Female 45 13 (29) .525 0.7
Source BM 60 15 (25) 1
CB 27 11 (41) .095 2.0
PBSC (+ BM) 15 7 (47) .073 2.2
Indication Malignancy 46 18 (55)
Nonmalignancy 56 15 (45) .225 0.6
APPENDIX 2: Cox regression models of busulfan (Bu)
and matched (B) patients.
Cox regression models of busulfan (Bu) exposure in rel
tients. (A) The event (death, relapse, or graft failure), whic
age categories and their corresponding exposure to busulfan
play of the mean data) for the EFS of all data is shown. A t
b3*AUC
3 1 age, describes these data (black line). (B) The e
matched patient, divided into 2 age categories and their corr
The Loess curves (which is a display of the mean data) for th
shown. A parabola (b1*AUC 1 b2*AUC
2) describes these d47. El KN, Legouvello S, Joseph CM, et al. High-resolution HLA
class I and II typing and CTLp frequency in unrelated donor
transplantation: a single-institution retrospective study of 69
BMTs. Bone Marrow Transplant. 2001;27:35-43.
48. Yu LC, Wall DA, Sandler E, et al. Unrelated cord blood trans-
plant experience by the pediatric blood and marrow transplant
consortium. Pediatr Hematol Oncol. 2001;18:235-245.
49. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of
HLA class I and class II high-resolution matching on outcomes
of unrelated donor bone marrow transplantation: HLA-C
mismatching is associated with a strong adverse effect on trans-
plantation outcome. Blood. 2004;104:1923-1930.
50. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation
from unrelated donors for treatment of hematologic malignan-
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f Covariates of EFS and OS
OS
R 95% CI Deaths, n (%) P HR 95% CI Lower
8 (38) 1
3 0.27 to 1.96 6 (30) .476 0.68 0.24 to 1.96
2 0.25 to 2.06 5 (25) .395 0.61 0.19 to 1.92
1 0.05 to 0.90 2 (11) .042 0.18 0.03 to 0.94
3 0.21 to 1.86 7 (35) .751 0.84 0.28 to 2.54
10 (18) 1
0 1.40 to 5.98 18 (40) .019 2.58 1.17 to 5.66
13 (22) 1
1 0.91 to 4.91 15 (35) .128 1.82 0.84 to 3.92
12 (32) 1
5 0.52 to 2.56 16 (25) .563 0.77 0.31 to 1.88
19 (24) 1
2 0.80 to 4.10 9 (39) .176 1.84 0.76 to 4.44
2 (11) 1
9 1.11 to 19.8 26 (31) .082 3.62 0.85 to 15.4
9 1.02 to 1.16 .020 1.09 1.01 to 1.17
16 (28) 1
9 0.39 to 1.62 12 (27) .917 0.96 0.44 to 2.07
11 (18) 1
6 0.88 to 4.80 10 (37) .038 2.74 1.06 to 7.10
8 0.93 to 5.62 7 (47) .019 3.14 1.21 to 8.14
16 (57)
5 0.33 to 1.30 12 (43) .164 0.59 0.28 to 1.24
exposure in relation to EFS for mismatched (A)
ation to EFS for mismatched (A) and matched (B) pa-
h occurred in each mismatched patient, divided into 3
(1, event; 0, no event). The Loess curve (which is a dis-
hird-order polynomial model, b1*AUC 1 b2*AUC
2 1
vent (death, relapse, or graft failure) occurring in each
esponding exposure to busulfan (1, event; 0, no event).
e event free survival of the data in both age categories is
ata of patients under agen 10 years (black line).
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